Company Overview and News

 
Page Industries Limited - Updates

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PGDQY PAGEIND 532827

 
Page Industries Limited - Shareholders meeting

2018-08-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PGDQY PAGEIND 532827

 
40 stocks to turn ex-dividend

2018-08-20 thehindubusinessline
About 40 companies will turn ex-dividend on Thursday. Investors wishing to receive the payouts need to buy these companies’ shares by Tuesday. Among these are Alkem Labs (₹7/share), CUB (₹0.30), Dynamatic Tech (₹2), Escorts (₹2), GNFC (₹7.50), Gujarat Fluorochem (₹3.50), Hinduja Global (₹2.5), HSIL (₹4), JBM Auto (₹2), KIOCL (₹0.79), KSE (₹60), MCX (₹17), Nalco (₹1), Manappuram (₹0.55), Page Industries (₹41), Radico Khaitan (₹1), Rupa & Co (₹3) and Sarda Energy (₹5).
PGDQY 532497 PAGEIND 532827 RADICO 532605 JBMA

 
Shares of Page Industries touch 52-week high on bourses

2018-08-20 thehindubusinessline
Shares of Page Industries today rose for the fifth consecutive session and rose 3 per cent to its 52-week high of Rs 35,049.90 on the bourses. On August 13, MSCI, a provider of benchmark indices globally, had said that Page Industries has been added in the MSCI India Domestic Index.
PGDQY PAGEIND 532827

 
Check out top 10 stocks which moved the most last week; HDIL registers 50% gain

2018-08-19 moneycontrol
The market ended a truncated week on a good note, as benchmark indices closed with strong gains. The Nifty ended the day at a record closing high, while the Sensex ended higher by almost 300 points. Having said that, it failed to hold 38,000-mark.
PAGEIND 500449 UBL 532978 533155 TTNQY JUBLFOOD 532478 FILATEX RAIN BIRLAPREC 532540 JBLWY 509488 526227 522105 PGDQY EXIDEIND 517354 HVLQY GRAPHITE 532827 500339 UBHOLDINGS UNBWY HOCL EXQDY BAJAJFINSV BATAINDIA HAVELLS TCS 500086 507458 500043

 
Page Industries hits new high on robust Q1 results

2018-08-14 thehindubusinessline
The five-digit stock price did not deter investors from lapping up the stock of Page Industries, thanks to its phenomenal show in the June 2018 quarter and continued strong outlook. The company’s shares jumped 3.4 per cent on Tuesday before touching a new all-time high of ₹34,200 on the BSE; it is up more than 10 per cent in just four trading sessions.
PGDQY PAGEIND 532827

 
An evening walk down Dalal Street | Fresh all-time highs for indices, Sensex clinches 38,000 and ends above it; banks gain big

2018-08-09 moneycontrol
Looks like there’s no stopping the bulls. Not only are they in the driver’s seat for August 2018, they are ensuring that the car is in for a long drive.
NEXTMEDIA PAGEIND 532416 BHRQY 532215 532662 AXISBANK MS BHARTIARTL SBAZ PGDQY AXB IBN 532827 HTMEDIA SELAN AXBKY 532454 AXBA ICICIBANK 530075 532174

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00B1VJS64